

Special Issue on  
**Novel Regulators of Breast and Prostate Cancer**

# CALL FOR PAPERS

Breast and prostate cancer are amongst the most common cancers of men and women, and while patients presenting with localized disease generally have good prognosis, the outcome for those with advanced or metastatic disease remains poor. Derived from hormonally responsive epithelial tissues, breast and prostate cancer share many similarities, with common endocrine, transcriptional, and developmental regulators that control both normal development and function and also drive tumorigenesis.

Recent advances in high throughput 'omic' approaches have advanced personalized medicine strategies, tailoring treatment to the unique collection of genetic mutations and cooperating events that drive tumour progression and therapeutic resistance within an individual. Yet, despite the characterization of thousands of cancers, clinical practice has thus far remained largely unchanged due to several bottlenecks that include, but are not limited to, a lack of understanding of the functional consequences of genomic variants, a restricted suite of variant specific target therapeutics, and a poor understanding of the functional consequences of polygenic variant drivers of tumorigenesis. One of the main challenges that faces the field is the functional validation and characterization of these novel candidates and the development of effective pharmaceutical agents targeted at specific variants.

Investigators are invited to submit original research and review articles that identify and characterize novel regulators or demonstrate new functions for genes in the pathogenesis of breast and prostate cancer. We especially encourage articles that identify common regulators of breast and prostate cancer or provide a link between these two diseases.

Potential topics include but are not limited to the following:

- ▶ Identification of novel therapeutic targets in breast and prostate cancer
  - ▶ Functional validation of new candidates controlling mammary and prostate cancer cell phenotype, tumorigenesis, or metastasis
  - ▶ Characterization of transcriptional and signaling networks regulators that influence breast and prostate cancer pathogenesis
  - ▶ New insights into the mechanisms driving therapeutic resistance
  - ▶ Therapeutic or diagnostic biomarker development using novel polygenic or individual candidates

Authors can submit their manuscripts through the Manuscript Tracking System at <https://mts.hindawi.com/submit/journals/jo/noreg/>.

Papers are published upon acceptance, regardless of the Special Issue publication date.

**Lead Guest Editor**

Matthew J. Naylor, University of Sydney,  
Sydney, Australia  
[matthew.naylor@sydney.edu.au](mailto:matthew.naylor@sydney.edu.au)

**Guest Editors**

William J. Muller, McGill University,  
Montreal, Canada  
[william.muller@mcgill.ca](mailto:william.muller@mcgill.ca)

Samantha R. Oakes, Garvan Institute of  
Medical Research, Sydney, Australia  
[s.oakes@garvan.org.au](mailto:s.oakes@garvan.org.au)

**Submission Deadline**

Friday, 8 November 2019

**Publication Date**

March 2020